7 Hills Pharma LLC

7 Hills Pharma is a Houston-based clinical-stage biotech developing first-in-class integrin-targeted agonists designed to augment immunotherapies for cancer and stem cell transplantation. Its lead candidate alintegimod is an oral small molecule that selectively activates LFA-1 and VLA-4 integrins, currently in a Phase 1b/2a trial against anti-PD-1-resistant solid tumors backed by CPRIT and NIH non-dilutive funding.